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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced or metastat-
ic stage, when curative surgery is not recommended. Therefore, the prognosis is poor for this 
dismal disease, with only 1–2% of the patients reaching the 5-year survival follow-up. Current 
advances in systemic treatment with gemcitabine regimens, specifically polychemotherapy 
with gemcitabine plus nab-paclitaxel or other multidrug regimens such as FOLFIRINOX in the 
first line, have improved disease control over time. This higher efficacy of systemic treatment 
enables metastatic PDAC patients to receive second-line treatment more often nowadays. 
Currently, there is only one regimen for second-line treatment approved by the EMA, FDA, 
and Swissmedic, based on the phase III NAPOLI-1 study. In this case report, we present an 
outstanding response to sequential treatment with gemcitabine plus nab-paclitaxel followed 
by second-line treatment with nal-irinotecan plus 5-fluorouracil. © 2020 The Author(s)
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced or meta-
static stage, when curative surgery is not recommended. Therefore, the prognosis is poor for 
this dismal disease, with only 1–2% of the patients reaching the 5-year survival follow-up [1, 
2]. Current advances in systemic treatment with gemcitabine regimens, specifically polyche-
motherapy with gemcitabine plus nab-paclitaxel or other multidrug regimens such as 
FOLFIRINOX in the first line, have improved disease control over time [3]. This higher efficacy 
of systemic treatment enables metastatic PDAC (mPDAC) patients to receive second-line 
treatment more often nowadays. Currently, there is only one regimen for second-line 
treatment approved by the EMA, FDA, and Swissmedic, based on the phase III NAPOLI-1 study 
[4]. In this case report, we present an outstanding response to sequential treatment with 
gemcitabine plus nab-paclitaxel followed by second-line treatment with nal-irinotecan plus 
5-fluorouracil (5-FU).
Case
A 48-year-old Caucasian male patient presented to a regional hospital with a 3-week 
history of obstructive jaundice, pruritus, tea-colored urine, acholic stools, and fatigue. His 
weight was reported to be stable at that time, with obesity grade 1 and a BMI of 32.8 kg/m2. 
Collectively, his medical history included insulin-dependent diabetes mellitus, arterial hyper-
tension, and moderate obstructive sleep apnea syndrome as complications of his smoking 
history of 20 cumulative pack-years. He denied regularly drinking alcohol. He had no history 
of cancer and no tumors were noticed in his family.
Ultrasonography revealed dilated extrahepatic bile ducts with a hypoechogenic tumor at 
the pancreatic head. A following computed tomography (CT) scan revealed multiple enlarged 
peripancreatic lymph nodes and a tumor mass (23 × 15 mm) at the pancreatic head with no 
other tumor manifestations at that time. The tumor marker carbohydrate antigen 19-9 (CA19-9) was elevated at 5,700 kU/L (normal <24) and bilirubin was at 104 μmol/L (normal 
<21). Autoimmune pancreatitis was ruled out by a normal serum immunoglobulin G4 level.
The patient was transferred to our center for further diagnostics and interdisciplinary 
discussion of treatment. A following magnetic resonance imaging (MRI) scan of the liver and 
a fluorodeoxyglucose positron emission tomography-CT scan revealed a metabolically active 
tumor at the pancreatic head and multiple liver metastases (Fig. 1). Endoscopic retrograde 
cholangiopancreatography with stenting was performed, and fine-needle aspiration biopsy 
at the time of the endoscopic ultrasound demonstrated a cytology consistent with adenocar-
cinoma. During discussion within the multidisciplinary tumor board, all members recom-
mended the start of systemic chemotherapy.
At the time of diagnosis, the patient’s performance status (PS) was evaluated according 
to the Eastern Cooperative Oncology Group (ECOG) and was reported as grade 1: restricted 
in physically strenuous activity, but ambulatory and able to carry out light work. The CA19-9 
levels decreased adequately to 295 kU/L after stenting of the extrahepatic bile ducts as 
compared to the baseline value of the tumor marker before initiating systemic treatment. 
First-line treatment with the combination of nab-paclitaxel plus gemcitabine based on the 
MPACT [5] protocol was applied as the patient’s ECOG PS (at 1) and the bilirubin levels (at 54 μmol/L) were still elevated.
The patient tolerated 6 cycles of this chemotherapy combination, and restaging docu-
mented stable disease of the primary tumor and liver metastases on CT scans of the chest, 
abdomen, and pelvis and on MRI, respectively. The patient received a further 3 cycles of nab-
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paclitaxel plus gemcitabine. Unfortunately, after these 9 cycles of first-line treatment, the 
CA19-9 levels rose to 680 kU/L without signs of bile duct obstruction, and the tumor at the 
pancreatic head and the liver metastases were radiologically progressive on CT of the chest, 
abdomen, and pelvis and on MRI of the liver, respectively (Fig. 2b). At this stage, the 
progression after first-line treatment was discussed with the patient, and second-line 
treatment with nal-irinotecan in combination with 5-FU analogs according to the NAPOLI-1 
protocol was planned.
The ECOG PS remained stable at 1, supporting a continuation of this combination of nal-
irinotecan and 5-FU. Shortly after 2 cycles of this combination, the CA19-9 level dropped to 
230 kU/L, and planned restaging after 6 cycles revealed a partial response of the primary 
tumor and of the liver metastases on CT of the chest, abdomen, and pelvis and on liver MRI, 
respectively (Fig. 2c, d). This treatment success could be documented for all the following 
cycles, and recently, this patient has received the seventeenth cycle of second-line nal-irino-
tecan plus 5-FU. At the latest radiological and clinical evaluation, the CA19-9 level had dropped 
to 72 kU/L, and stable disease was still noticed in comparison to the response after 6 cycles. 
The patient did not suffer from any severe grade 3 or 4 toxicities, and it is worth noticing that 
the grade 2 anemia previously observed during first-line treatment had completely reverted 
to normal hematologic blood values.
To the best of our knowledge, this is one of the most extraordinary responses of mPDAC 
to treatment according to MPACT and NAPOLI-1 protocols; it even extends their presented 
progression-free survival (PFS) and overall survival (OS) rates by more than 4 months with 
a current PFS of 8.0 months and an OS of 17 months. Of note, we highlight that the quality of 
life (QoL) was high in this young and fit patient.
Fig. 1. Baseline partial-body positron emission tomography/computed tomography scan with 301-MBq flu-
orodeoxyglucose (18F-FDG). A, B Coronal (A) and sagittal plane (B) showing moderately increased FDG ac-
cumulation in the pancreatic head corresponding to pancreatic carcinoma. C Axial plane showing a 3-cm 
hypodense lesion in the pancreatic head with moderately increased FDG accumulation.
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Discussion
Algorithms for sequential management of patients with mPDAC based on expert opinions 
are emerging. The availability of more effective first-line treatments (the combination of nab-
paclitaxel plus gemcitabine and FOLFIRINOX based on the results of phase III studies) allows 
the development of second-line treatment options based on the results of phase II and III 
studies for patients with mPDAC [4–8]. On the other hand, the PANCREOX study did not 
demonstrate any difference in PFS or OS between infusional 5-FU/leucovorin (LV) and 
mFOLFOX6 (infusional 5-FU/LV and oxaliplatin), questioning the role of the addition of oxali-
platin for the management of patients previously treated with gemcitabine-based regimens 
[9].
Collectively, the results of the NAPOLI-1 study, which analyzed the effect of nal 
(nanoliposomal)-irinotecan alone or combined with 5-FU/LV in a phase III trial on patients 
with mPDAC previously treated with gemcitabine-based therapies, showed that this regimen 
Fig. 2. Abdominal magnetic resonance images showing multiple lesions in liver segments II, IVa, IVa/VIII, 
and VIII with 2 representative liver metastases shown in segment VIII (arrows). A At diagnosis, there were 
2 representative lesions 15 and 4 mm in size in segment VIII. B On progression after first-line chemotherapy 
with nab-paclitaxel/gemcitabine, the 2 lesions measured 14 and 8 mm. C Three months after treatment with 
second-line chemotherapy with nal-irinotecan/5-fluorouracil (5-FU), the lesions in liver segment VIII had 
regressed to 13 and 7 mm. D Eight months after treatment with second-line chemotherapy with nal-
irinotecan/5-FU, the lesions in liver segment VIII had regressed to 11 and 5 mm.
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prolongs survival (6.1 vs. 4.2 months), with a manageable safety profile [4]. Similar to other 
diseases like colon cancer, for example, the availability of second- and even third-line treat-
ments implies that the management of the disease should be viewed as a continuum of care 
with several lines of treatment rather than as compartmentalized treatments. However, there 
are no clear recommendations in the different guidelines available (e.g., NCCN or ESMO) 
regarding the optimal sequence of treatment for mPDAC. One of the main reasons is the lack 
of parallel comparison between possible approaches such as FOLFIRINOX and gemcitabine 
plus nab-paclitaxel or nal-irinotecan plus 5-FU in sequential treatments.
Due to the lack of randomized trials in the second-line setting after the combination of 
nab-paclitaxel plus gemcitabine as first-line treatment, one approach to determining results 
of second-line treatment is to analyze the outcomes of the patients who have received second-
line treatment after a first line with the combination of nab-paclitaxel plus gemcitabine in the 
MPACT trial [10].
One of the main goals of treating metastatic pancreatic cancer is to maintain health-
related QoL. Recently published data from the NAPOLI-1 study have demonstrated no dete-
rioration from baseline on most of the health-related QoL subscales (e.g., fatigue or physical 
or cognitive function), while survival was significantly prolonged [11].
Currently, there are no good predictive molecular markers favoring one chemotherapy 
regimen over any of the other available options. Moreover, no promising molecular markers 
for the personalized treatment of pancreatic cancer are available. Therefore, factors to be 
considered in making treatment decisions include the ECOG PS, comorbidities, residual toxic-
ities (i.e., neuropathy), prior treatments, and the patient’s goals and preferences. In summary, 
this case report highlighted factors such as a heightened ECOG PS, elevated bilirubin at 
baseline, and diabetes in favor of the nab-paclitaxel-plus-gemcitabine regimen instead of 
FOLFIRINOX as first-line treatment.
Conclusion
Sequential treatment of metastatic pancreatic cancer will change survival rates with this 
dismal disease. Here, we could show a quite sufficient and effective sequence for a young and 
fit patient following MPACT and NAPOLI-1 study protocols with which the patient’s QoL 
remained high.
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